Faeth Therapeutics Inc. Common Stock (FTH)

About FTH

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

29

Website

www.faeththerapeutics.com

Fundamentals

1-day range

$28.73$33.2

Market cap

$704.79M

P/E (trailing)

—

P/E (forward)

-6.52

EPS (trailing)

$-60.86

Dividend yield

—

Beta

-0.31

Avg. volume

180.8K

Forecasts

10 analyst ratings

Faeth Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• FTH

  Faeth Therapeutics Inc. Common Stock

  $33.84

  ▲ 0.30%
  Market cap $704.79MP/E —
  $7.21$37.9
• CTMX

  CytomX Therapeutics Inc. Common Stock

  $3.22

  ▼ 5.99%
  Market cap $690.12MP/E —
  $1.9$8.21
• OCS

  Oculis Holding AG Ordinary shares

  $12.21

  ▼ 1.77%
  Market cap $689.43MP/E —
  $10.52$34.48
• DRUG

  Bright Minds Biosciences Inc. Common Stock

  $72.74

  ▼ 2.41%
  Market cap $723.93MP/E —
  $53.99$170
• CLYM

  Climb Bio Inc. Common Stock

  $14.56

  ▼ 3.32%
  Market cap $676.28MP/E —
  $1.54$18.33
• MNPR

  Monopar Therapeutics Inc. Common Stock

  $112.17

  ▼ 1.55%
  Market cap $747.88MP/E —
  $32.04$124.82
• BBOT

  BridgeBio Oncology Therapeutics Inc. Common Stock

  $8.74

  ▼ 4.79%
  Market cap $660.88MP/E —
  $7$14.87

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
  Benzinga · 8/21/2026
• Needham Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $56
  Benzinga · 8/21/2026
• Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
  Yahoo · 8/17/2026
• Faeth Therapeutics Says FDA Grants Fast Track Designation To Combination Of Sapanisertib And Serabelisib With Paclitaxel For Treatment Of Patients With Endometrial Cancer
  Benzinga · 8/17/2026
• Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
  Yahoo · 8/14/2026
• Faeth Therapeutics: PI3K Pathway Inhibitor With Key Data Catalyst In Play Intrigues
  SeekingAlpha · 8/11/2026
• HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target
  Benzinga · 8/11/2026
• Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Yahoo · 8/7/2026

• Anand Kiran Parikh · July 21, 2026 · Grant

  398.0K
• Craver Josiah · July 21, 2026 · Grant

  30.8K
• Brian C. Stephenson · July 1, 2026 · Buy

  600 @ $24.22
• Brian C. Stephenson · July 1, 2026 · Buy

  4.4K @ $23.4
• Brian C. Stephenson · June 30, 2026 · Buy

  4.3K @ $24.98
• Brian C. Stephenson · June 30, 2026 · Buy

  1.6K @ $23.88
• Brian C. Stephenson · June 30, 2026 · Buy

  1.9K @ $22.95
• Brian C. Stephenson · June 29, 2026 · Buy

  831 @ $23.34

Institutional Ownership

March 31, 2026

Total shares held

2.51M

Total value held

$77.32M

Institutional holders

29